Peli™ Products, is a global player in the design and manufacture of high-performance protective cases and advanced lighting solutions. COVID-19 vaccines and therapies are rapidly becoming available but require a safely distribution within a certain temperature range, a problem that Peli’s BioThermal™ division is helping solve with its temperature-controlled packaging.
To ensure the cold chain is maintained throughout the vaccine or therapy’s journey, Peli has adapted their existing products to provide deep frozen temperatures when required for the newly developed life sciences materials.
“We know that pharmaceutical companies are in all phases of the development process for vaccines and therapeutics and working tirelessly to bring safe and effective drug products to market quickly,” said Greg Wheatley, Vice President of Worldwide New Product Development and Engineering at Peli BioThermal. “Our engineering team matched this urgency to ensure they have the correct temperature-controlled packaging to meet them where they’re at in drug development for the pandemic recovery, from discovery to distribution.”
Peli BioThermal’s deep frozen products use phase change material (PCM) and dry ice systems to provide frozen payload protection with durations from 72 hours to 144+ hours. Payload capacities range from 1 to 96 litres for parcel shippers and 140 to 1,686 litres for pallet shippers.
New deep-frozen solutions are ideal for short-term vaccine storage, redirect courier transport of vaccines from freezer farm hubs to immunisation locations and daily vaccine replenishment to remote and rural areas.
Peli BioThermal temperature-controlled packaging is currently being used to distribute COVID-19 vaccines and therapeutics, either directly or through global transportation providers, in Denmark, France, Italy, Germany, Spain, Sweden, and the UK as well as in Kuwait and Saudi Arabia in the Middle East, with more countries set to join the list as the pandemic recovery process rolls out.